28
Participants
Start Date
June 30, 2005
Primary Completion Date
August 31, 2009
Study Completion Date
August 31, 2009
Bavituximab
Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).
The West Clinic, Memphis
University of Texas Southwestern Medical Center, Dallas
Scott & White Hospital, Center for Cancer Prevention and Care, Temple
MD Anderson Cancer Center, Houston
Arizona Cancer Center, Tucson
Premiere Oncology, Santa Monica
Lead Sponsor
Peregrine Pharmaceuticals
INDUSTRY